Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020. The filing identifies the registrant as Celsion Corporation; the request metadata names Imunon, Inc., so investors should verify the entity and filing identity. Celsion is a clinical-stage oncology company developing ThermoDox, GEN-1 and nucleic-acid therapy platforms. It reports no significant product revenue.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $250,000 | $250,000 |
| Research and development | $2.99 million | $3.56 million | $6.04 million | $6.33 million |
| General and administrative | $1.90 million | $2.14 million | $3.74 million | $4.35 million |
| Operating loss | $4.77 million | $5.57 million | $9.53 million | $10.43 million |
| Net loss | $5.34 million | $5.90 million | $10.40 million | $8.27 million |
| Basic and diluted loss per share | $0.18 | $0.29 | $0.37 | $0.42 |
At June 30, 2020, cash and cash equivalents were $22.65 million and available-for-sale debt securities were $2.79 million; including accrued interest, liquid resources totaled approximately $25.45 million. Current assets were $26.80 million, current liabilities $9.21 million, and working capital $17.59 million. Total liabilities were $22.51 million. Horizon debt had approximately $10.0 million of principal remaining, with principal-and-interest amortization scheduled to begin August 1, 2020. The company reported $301 million of accumulated losses.
For the first six months, operating cash use was $7.92 million; investing activities provided $5.15 million, primarily from net maturities and sales of investments; and financing activities provided $18.55 million, primarily from equity issuance. The company issued approximately 9.4 million shares through financing facilities for $18.18 million net proceeds and raised approximately $9.1 million net in a June offering. It also received and repaid two PPP loans totaling $1.32 million. No gross or operating margin is presented; the filing’s revenue is limited to licensing revenue.
Material changes versus the prior comparable period
- Six-month operating expenses declined 8.4%, mainly from lower clinical research and general and administrative costs, partly offset by higher manufacturing and chemistry, manufacturing and controls spending.
- Six-month net loss increased from $8.27 million to $10.40 million. The 2019 period included a $3.00 million non-cash gain from the revaluation of the EGEN earn-out liability; 2020 recorded a $0.30 million non-cash charge instead.
- Cash and cash equivalents increased from $6.88 million at year-end 2019 to $22.65 million at June 30, 2020, reflecting equity financing and investment maturities. Outstanding common shares rose from 23.26 million to 33.23 million.
Outlook, commentary, risks and unusual items
- ThermoDox/OPTIMA: After quarter-end, the independent monitoring committee recommended considering stopping the Phase III OPTIMA study after its July 9 interim analysis crossed the prespecified futility boundary (0.903 versus 0.900). The company reported no safety concerns. On August 4, it said it would continue following patients for overall survival while reviewing the data; management noted a possible data-maturity issue. This is a significant clinical and valuation risk for the program.
- GEN-1: The Phase I/II OVATION 2 study was progressing, and the first two patients were randomized into its Phase II portion on July 27. The company anticipated completing enrollment of up to 118 patients in the third quarter of 2021.
- Liquidity outlook: Management said available resources, potential proceeds from selling remaining New Jersey net operating losses, and unused capacity under its JonesTrading equity sales agreement were expected to fund operations through the end of 2021. This estimate is assumption-dependent; the company expects continuing losses and may require additional financing, which could dilute shareholders.
- COVID-19: No significant business or operating impact was observed through June 30, but the company warned that the pandemic could affect trials, enrollment, suppliers, financing access and future cash flows.
- Other items: A shareholder lawsuit settlement proposed repricing certain options and paying $187,500 in plaintiff legal fees; final court approval was still pending. The EGEN earn-out liability was $6.02 million at June 30 and is contingent on milestones. A $1.8 million sale of New Jersey net operating losses was completed in April; an application to sell a further approximately $2.0 million remained pending.
- Disclosure inconsistency: The MD&A narrative gives Q2 2020 and 2019 net losses of $5.1 million and $2.4 million, which conflict with the financial statements’ $5.34 million and $5.90 million. The financial statements are used above; investors should check the filed statements and any related correction or clarification.
Key facts for investors to verify
- Confirm the registrant identity and reconcile the Imunon metadata with the Celsion filing.
- Review subsequent disclosures on the OPTIMA interim results, continued overall-survival follow-up and any final trial decision.
- Validate the company’s projected runway against cash burn, debt amortization, remaining equity-facility capacity and the pending NOL sale.
- Assess dilution from recent share issuance and outstanding options and warrants.
- Check the final court disposition of the shareholder settlement and the conditions and timing of any EGEN milestone payment.